Polypharmacy Pattern in Iran: A Comprehensive Analysis of a Large Prescription Database.

IF 1.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Reza Ebrahimoghli, Ali Janati, Hojatolah Gharaee, Mir Hossein Aghaei
{"title":"Polypharmacy Pattern in Iran: A Comprehensive Analysis of a Large Prescription Database.","authors":"Reza Ebrahimoghli,&nbsp;Ali Janati,&nbsp;Hojatolah Gharaee,&nbsp;Mir Hossein Aghaei","doi":"10.5812/ijpr-131304","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy is a significant patient safety concern.</p><p><strong>Objectives: </strong>This study aims to estimate the prevalence of polypharmacy, its continuity and associated factors, and common medication classes among a large outpatient population in East Azerbaijan province, Iran.</p><p><strong>Methods: </strong>A retrospective prescription data analysis was performed. The cohort included all ≥ 20 years old subjects with at least one prescription filled during the main three-month study period (2020 March 1 - 2020 May 31). Polypharmacy was defined as being exposed to more than four different medications during the main study period, and continuous polypharmacy was defined as being exposed to more than four medications during both the main study period and follow-up period (2020 October 1 - 2020 December 31). The frequency and prevalence of polypharmacy, along with predictive factors, were estimated. We performed multivariate logistic regression and estimated odds ratios (ORs) to investigate the risk factors for polypharmacy.</p><p><strong>Results: </strong>307,820 patients included (mean age 49.8 years, 62.9% female, mean drug use 3.7 (SD = 2.6). Polypharmacy was observed in 28.3% (CI: 28.1 - 28.4), of which 36.6% experienced continuous polypharmacy. The odds of being exposed to polypharmacy increased with being female, increasing age, and exposure to chronic conditions. The groups of medications most utilized by polypharmacy patients were those indicated for gastro-esophageal reflux diseases, beta-blocking agents, antidepressants, blood glucose-lowering drugs, and antithrombotic agents.</p><p><strong>Conclusions: </strong>Strategies should be formulated to inform healthcare policymakers and providers about the magnitude of the polypharmacy phenomenon, associated factors, and the common medication classes involved.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e131304"},"PeriodicalIF":1.8000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/5e/ijpr-21-1-131304.PMC10007994.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr-131304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Polypharmacy is a significant patient safety concern.

Objectives: This study aims to estimate the prevalence of polypharmacy, its continuity and associated factors, and common medication classes among a large outpatient population in East Azerbaijan province, Iran.

Methods: A retrospective prescription data analysis was performed. The cohort included all ≥ 20 years old subjects with at least one prescription filled during the main three-month study period (2020 March 1 - 2020 May 31). Polypharmacy was defined as being exposed to more than four different medications during the main study period, and continuous polypharmacy was defined as being exposed to more than four medications during both the main study period and follow-up period (2020 October 1 - 2020 December 31). The frequency and prevalence of polypharmacy, along with predictive factors, were estimated. We performed multivariate logistic regression and estimated odds ratios (ORs) to investigate the risk factors for polypharmacy.

Results: 307,820 patients included (mean age 49.8 years, 62.9% female, mean drug use 3.7 (SD = 2.6). Polypharmacy was observed in 28.3% (CI: 28.1 - 28.4), of which 36.6% experienced continuous polypharmacy. The odds of being exposed to polypharmacy increased with being female, increasing age, and exposure to chronic conditions. The groups of medications most utilized by polypharmacy patients were those indicated for gastro-esophageal reflux diseases, beta-blocking agents, antidepressants, blood glucose-lowering drugs, and antithrombotic agents.

Conclusions: Strategies should be formulated to inform healthcare policymakers and providers about the magnitude of the polypharmacy phenomenon, associated factors, and the common medication classes involved.

Abstract Image

伊朗的多种药房模式:对大型处方数据库的综合分析。
背景:多种用药是一个重要的患者安全问题。目的:本研究旨在估计伊朗东阿塞拜疆省大量门诊人群中多种用药的流行程度、连续性和相关因素以及常见药物类别。方法:回顾性处方资料分析。该队列包括所有≥20岁的受试者,在主要的三个月研究期间(2020年3月1日至2020年5月31日)至少配药一次。多重用药定义为在主要研究期间暴露于四种以上不同药物,持续多重用药定义为在主要研究期间和随访期间(2020年10月1日至2020年12月31日)暴露于四种以上药物。估计了多种用药的频率和流行程度,以及预测因素。我们采用多变量逻辑回归和估计优势比(ORs)来调查多药的危险因素。结果:共纳入307820例患者,平均年龄49.8岁,女性62.9%,平均用药3.7例(SD = 2.6)。28.3% (CI: 28.1 ~ 28.4)患者为多药,其中36.6%持续为多药。暴露于多种药物的几率随着女性、年龄的增长和慢性疾病的暴露而增加。多药患者最常使用的药物是用于胃食管反流疾病的药物、β -阻滞剂、抗抑郁药、降血糖药和抗血栓药。结论:应制定策略,告知卫生保健决策者和提供者有关多药现象的严重性、相关因素和涉及的常见药物类别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
6.20%
发文量
52
审稿时长
2 months
期刊介绍: The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信